US Patent

US9808468 — Formulation of meloxicam

Method of Use · Assigned to Iceutica Pty Ltd · Expires 2035-03-31 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a formulation of meloxicam in unit dosage forms containing 5 mg or 10 mg of meloxicam for pain relief.

USPTO Abstract

Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.

Drugs covered by this patent

Mobic (MELOXICAM) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2165`	—	Mobic
`U-2160`	—	Mobic

Patent Metadata

Patent number: US9808468
Jurisdiction: US
Classification: Method of Use
Expires: 2035-03-31
Drug substance claim: No
Drug product claim: No
Assignee: Iceutica Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.